Literature DB >> 27733658

Postnatal Cardiovascular Consequences in the Offspring of Pregnant Rats Exposed to Smoking and Smoking Cessation Pharmacotherapies.

Kathirvel Gopalakrishnan1, Amar S More1, Gary D Hankins1, Tatiana N Nanovskaya1, Sathish Kumar1.   

Abstract

Approximately 20% of pregnant women smoke despite intentions to quit. Smoking cessation drugs, such as nicotine replacement therapy (NRT) and bupropion, are recommended treatments. Adverse cardiovascular outcomes in offspring have raised concerns about NRT's safety during pregnancy. However, the effect of bupropion is unknown. Using a rat model, we determined whether NRT and bupropion interventions during pregnancy are safer than continued smoking on offspring's cardiovascular function. Male offspring of controls and dams exposed to cigarette smoke (1.6 packs/day, inhalation), nicotine (2 mg/kg/d subcutaneously), and bupropion (13 mg/kg twice daily orally) were assessed for fetoplacental weight, cardiac function, blood pressure, and vascular reactivity. Fetoplacental weights were decreased and spontaneous beating and intracellular calcium in neonatal cardiomyocytes were increased in smoking, nicotine, and bupropion offspring; however, these effects were more accentuated in smoking followed by nicotine and bupropion offspring. Increased heart rate and decreased cardiac output, stroke volume, and left ventricular percent posterior wall thickening were observed in smoking, nicotine, and bupropion offspring. The left ventricular mass was reduced in smoking and nicotine but not in bupropion offspring. Blood pressure was higher with decreased endothelium-dependent relaxation and exaggerated vascular contraction to angiotensin II in smoking and nicotine offspring, with more pronounced dysfunctions in smoking than nicotine offspring. Maternal bupropion did not impact offspring's blood pressure, endothelium-dependent relaxation, and vascular contraction. In conclusion, maternal nicotine intervention adversely affects offspring's cardiovascular outcomes, albeit less severely than continued smoking. However, bupropion causes cardiac derangement in offspring but does not adversely affect blood pressure and vascular function.

Entities:  

Keywords:  bupropion; cardiac function; nicotine; offspring; vascular function

Mesh:

Substances:

Year:  2016        PMID: 27733658      PMCID: PMC5933098          DOI: 10.1177/1933719116673199

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  98 in total

Review 1.  Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights.

Authors:  Neil E Paterson
Journal:  Eur J Pharmacol       Date:  2008-12-16       Impact factor: 4.432

2.  Effects of transdermal nicotine or smoking on nicotine concentrations and maternal-fetal hemodynamics.

Authors:  C A Oncken; H Hardardottir; D K Hatsukami; V R Lupo; J F Rodis; J S Smeltzer
Journal:  Obstet Gynecol       Date:  1997-10       Impact factor: 7.661

3.  Partial inhibition of Na+/K+-ATPase by ouabain induces the Ca2+-dependent expressions of early-response genes in cardiac myocytes.

Authors:  M Peng; L Huang; Z Xie; W H Huang; A Askari
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

4.  Protein kinase C signaling transduces endorphin-primed cardiogenesis in GTR1 embryonic stem cells.

Authors:  Carlo Ventura; Elisabetta Zinellu; Emiliana Maninchedda; Marina Fadda; Margherita Maioli
Journal:  Circ Res       Date:  2003-03-06       Impact factor: 17.367

Review 5.  Protein kinase C isoform diversity in the heart.

Authors:  S F Steinberg; M Goldberg; V O Rybin
Journal:  J Mol Cell Cardiol       Date:  1995-01       Impact factor: 5.000

6.  Maternal smoking and blood pressure in 7.5 to 8 year old offspring.

Authors:  R Morley; C Leeson Payne; G Lister; A Lucas
Journal:  Arch Dis Child       Date:  1995-02       Impact factor: 3.791

7.  Augmented rififylin is a risk factor linked to aberrant cardiomyocyte function, short-QT interval and hypertension.

Authors:  Kathirvel Gopalakrishnan; Eric E Morgan; Shane Yerga-Woolwine; Phyllis Farms; Sivarajan Kumarasamy; Andrea Kalinoski; Xiaochen Liu; Jian Wu; Lijun Liu; Bina Joe
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

8.  Maternal smoking during pregnancy and childhood lymphoma: a meta-analysis.

Authors:  C N Antonopoulos; T N Sergentanis; C Papadopoulou; E Andrie; N Dessypris; P Panagopoulou; S Polychronopoulou; A Pourtsidis; F Athanasiadou-Piperopoulou; M Kalmanti; V Sidi; M Moschovi; E T Petridou
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

Review 9.  Biological aspects of the link between smoking and depression.

Authors:  E Quattrocki; A Baird; D Yurgelun-Todd
Journal:  Harv Rev Psychiatry       Date:  2000-09       Impact factor: 3.732

10.  Psychiatric comorbidity of smoking and nicotine dependence.

Authors:  N Breslau
Journal:  Behav Genet       Date:  1995-03       Impact factor: 2.805

View more
  3 in total

1.  Maternal perfluorooctane sulfonic acid exposure during rat pregnancy causes hypersensitivity to angiotensin II and attenuation of endothelium-dependent vasodilation in the uterine arteries †.

Authors:  Sri Vidya Dangudubiyyam; Jay S Mishra; Ruolin Song; Sathish Kumar
Journal:  Biol Reprod       Date:  2022-10-11       Impact factor: 4.161

2.  Inhibition of DNA methylation in newborns reprograms ischemia-sensitive biomarkers resulting in development of a heart ischemia-sensitive phenotype late in life.

Authors:  Yanyan Zhang; Meizi Yang; Yong Li; Bailin Liu; Lubo Zhang; Daliao Xiao
Journal:  Reprod Toxicol       Date:  2021-09-15       Impact factor: 3.421

3.  Reprogramming of miR-181a/DNA methylation patterns contribute to the maternal nicotine exposure-induced fetal programming of cardiac ischemia-sensitive phenotype in postnatal life.

Authors:  Jie Jian; Peng Zhang; Yong Li; Bailin Liu; Yanyan Zhang; Lubo Zhang; Xuesi M Shao; Jian Zhuang; Daliao Xiao
Journal:  Theranostics       Date:  2020-09-26       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.